key: cord-0861359-vuxjkdmo
authors: Zhang, Hua; Han, Han; He, Tianhui; Labbe, Kristen E; Hernandez, Adrian V; Chen, Haiquan; Velcheti, Vamsidhar; Stebbing, Justin; Wong, Kwok-Kin
title: Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis
date: 2020-11-02
journal: J Natl Cancer Inst
DOI: 10.1093/jnci/djaa168
sha: 138786b193f86734ef7ec73bfb7734f191471c0b
doc_id: 861359
cord_uid: vuxjkdmo

BACKGROUND: Previous studies have indicated Coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate. METHODS: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariate logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes. RESULTS: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the UK and Europe, followed by the USA and Canada (35.7%) and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (odds ratio [OR] = 3.57; 95% CI = 1.80 to 7.06), male (OR = 2.10; 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00; 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariate analysis, only age greater than 65 years (OR = 3.16; 95% CI = 1.45 to 6.88) and being male (OR = 2.29; 95% CI = 1.07 to 4.87) were associated with increased risk of severe events. CONCLUSION: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate when compared with that of COVID-19 patients without cancer. Age and gender appear to be risk factors associated with a poorer prognosis.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has spread rapidly around the world since it emerged in late 2019 in China [1] [2] [3] . In early March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a global pandemic and as of 15 th of July, this virus has infected nearly 14 million individuals with 580,000 deaths [4] . As the number of new cases continues to rise, challenges to the global health-care system remain.

Cancer is one of the leading causes of death, with an estimated 9.6 million deaths worldwide in 2018 [5] . Compared with the general population, cancer patients are more vulnerable to infection [6, 7] . In addition to being in immunosuppressive states directly caused by cancer itself as well as cytotoxic treatments, this population presents an overall poorer health status, tends to be older, and has coexisting medical conditions. These are all risk factors that could contribute to severe COVID-19 infection [3, [8] [9] [10] and lead to a potentially poorer prognosis and an increased risk of death.

The challenges facing the health care and research community have been unprecedented in response to the COVID-19 pandemic, prompting several national and international collective efforts dedicated to understanding the impact of COVID-19 on cancer patients [11] [12] [13] . For instance, The COVID-19 and Cancer Consortium (CCC19) is a multicenter registry that includes more than 90 institutions from the USA, Canada and Spain [12] . It aims to collect and analyze observational data from cancer patients with COVD-19 to inform clinical practice in real-time. In addition, clinicians and scientists from over 28 countries initiated another global consortium: The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, dedicated to studying the effects of COVID-19 on patients with thoracic malignancies [11] . 5 Effects of the COVID-19 pandemic on patients with cancer have been detrimental and profound [12] . Current evidence based on individual reports from China suggests that cancer patients infected with COVID-19 may be at an increased risk of severe events, including hospitalization, admission to the intensive care unit, or requiring invasive ventilation, or death [6, 14, 15] . Preliminary analysis of data from the CCC19 and TERAVOLT cohorts also suggest a higher risk of fatality in cancer patients [10, 16] .

Although these individual reports provide valuable data on the clinical outcome of cancer patients with COVID-19, the majority of the studies analyzed have a small sample size or are limited by geographical regions (eg. either China or Europe or USA) or one cancer type (thoracic malignancies in the TERAVOLT). It is crucial to assess the data collected from these individual studies and evaluate in a systematic manner.

Using data from 15 cohort studies involving 3019 patients, this meta-analysis aims to comprehensively characterize the clinical features, outcome of cancer patients with COVID-19, and the potential risk factors contributing to higher fatality. Findings from this analysis will improve our understanding of the impact of the COVID-19 pandemic on cancer patients and highlight the urgent need to provide optimal clinical management to this vulnerable patient population.

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [17] . 6 

We included all studies that reported case fatality or severe events in cancer patients with COVID-19. Clinical practice guidelines and recommendations, editorials, commentaries, and review articles were excluded. Publications that were not subject to peer review were also excluded.

Databases including PubMed, Embase and conference proceedings were searched on June 9 2020, using the following terms: "(coronavirus OR COVID-19 OR SARS-CoV-2 or COVID-2019) AND (cancer OR carcinoma OR neoplasm OR malignancy)". No limitation was placed regarding publication language but publication date was restricted to 2019 and 2020 considering the timeline of the COVID-19 outbreak. Duplicate records were excluded. References from review articles, commentaries, editorials, included studies, and conference publications of relevant medical societies were reviewed and crossreferenced to ensure completeness. Full-text articles that were considered eligible in the initial screening were re-evaluated. We (H.Z. and H.H.) performed study selection independently and extracted all the data. T.H. conducted independent verification. Study characteristics, including first author, patient number, age, gender, geographical region of residence, comorbidity (hypertension, cardiovascular disease and diabetes), common COVID-19 symptoms (fever, dyspnea and cough), cancer type (lung, other solid tumor (breast, prostate, gastrointestinal, gynecological, renal cell, endocrine, melanoma, head and neck, sarcoma, nervous system) and hematological malignancies 7 (lymphoid neoplasms, multiple myeloma, non-Hodgkin lymphoma, myeloid neoplasms, acute myeloid leukemia, acute lymphoblastic leukemia)), cancer treatment type (surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy), and clinical outcomes (survivor or non-survivor or severe events) were extracted.

The quality of included cohort studies was assessed by two researchers independently using the Newcastle-Ottawa Scale (NOS) [18] . Specifically, the NOS scale evaluates the following criteria: Selection: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, and demonstration that outcome of interest was not present at start of study; Comparability: comparability of cohorts on the basis of the design or analysis; Outcome: assessment of outcome, whether the follow-up was long enough for outcomes to occur, and adequacy of follow up of cohorts. The NOS assessment was performed per each cohort study, which were assigned scores based on these 3 criteria (selection, comparability, outcomes). The maximum score was 9 and the minimum score was 0. A score of 7 or more was reflective of high methodological quality; a score of 5 or 6 indicated moderate quality and a score of 4 or less indicated low quality.

Meta-analysis was performed using R statistical software (version 3.6.1). Random-effects analysis was used for all meta-analyses, due to the clinical heterogeneity inherent in the 8 data and the different effect sizes of included studies. We used the DerSimonian and Laird method for the estimator of between-study variance  2 [19] . In random effects model, weights are equal to the inverse of the sum of within-study variance plus the betweenstudy variance; weights are similar among studies, and therefore large studies lose influence and small studies gain influence for the overall effect [20] . The Cochran's Q statistic is a type of Chi-square test that identifies the presence of heterogeneity when its P < .05. The statistic I 2 describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance), and was calculated to quantity the heterogeneity across studies [21] . A value of 0.0% indicates no observed heterogeneity, and larger values show increasing heterogeneity [21] ; I 2 > 75.0% is considered high heterogeneity. I 2 is equal to 100.0% x (Q -df)/Q, where Q is Cochran's Q statistic and df the degrees of freedom. We report Cochran's Q statistic, the P value and I 2 per meta-analysis.

Case fatality rate (calculated as the ratio of the number of deaths/number of cases) or severe event rate (calculated as the ratio of the number of patients with severe events/number of cases) and its 95% confidence interval (CI) for the overall population and subgroup analyses in an individual study were calculated. A composite 'severe event' endpoint was defined here based on the individual being admitted to the intensive care unit, or requiring invasive ventilation, or death. Patients with missing values were excluded from analysis.

Publication bias was assessed by the funnel plots and Egger's test [22] (P < .05 was considered to be suggestive of a statistically significant publication bias). Based on the quality assessment of study, sensitivity analysis was performed excluding low quality 9 studies (case series studies) or excluding the cohort studies with moderate quality. In addition, a separate sensitivity analysis using 'leaving-one-out' per time approach was performed.

Individual patient data on demographic or clinical characteristics including age, gender, comorbidities (hypertension, diabetes, or cardiovascular disease), cancer type (hematological malignancy, lung or other solid cancer) and treatment (chemotherapy, immunotherapy, targeted therapy, radiotherapy or surgery) and associated outcomes (survivor or non-survivor, or severe events) were extracted from three available studies [6, 14, 15] . In the individual patient data analyses, univariate and multivariate logistic regression analysis were used to estimate odds ratio (OR) and 95% CIs of the association of each variable with the outcomes of cancer patients with COVID-19. The variables (demographic and clinical characteristics as listed above) were pre-specified by investigators. Variables with P values < .05 from univariate analysis are considered as candidates for multivariate logistic model, which assessed their association with outcome.

All reported P values are 2-sided, and P < .05 was used to indicate statistical significance.

The literature search identified 4051 references through database mining and 2 from conference proceedings. After a full-text review of 21 studies, we identified 15 relevant studies including 2 from the 2020 AACR Annual Meeting proceedings for the metaanalysis (Figure 1) . These 15 studies, comprising of 5 case series [7, 15, [23] [24] [25] and 10 cohort studies [6, 10, 14, 16, [26] [27] [28] [29] [30] [31] , included patient data from institutions located in Europe, America and Asia. Patients included in these 15 studies were with active or previous malignancy, including solid tumors or hematological malignancies, who have either a laboratory-confirmed SARS-CoV-2 infection or a presumptive diagnosis of COVID-19.

Tables 1-4 list the main characteristics and clinical outcomes (survivor or non-survivor) of the 15 studies. In total, 3019 patients were included, of which 1628 (54.0%) were men and 1388 (46.0%) were women; more than half were over 65 years old ( Table 1) . All cohorts enrolled patients within the past six months since the outbreak of COVID-19 and all studies were published in the past four months. The most common geographical region of residence was the UK and Europe (41.0%), followed by the USA and Canada (35.7%) and Asia (China, 23.3%) ( Table 1) . Among the patients with reported comorbidity data, the 3 most common were hypertension (37.7%), diabetes (18.1%) and cardiovascular disease (13.1%) ( Table 1) . The most common presenting symptoms at time of hospital admission were cough and fever ( Table 2 ). 2 out of the 15 studies [24, 28] included patients with hematological malignancy only whereas 3 of them [7, 10, 15] were comprised of patients with solid tumor only ( Table 3) . The rest were mixed with both cancer types ( Table 4 ). All 15 studies reported at least one clinical outcome of cancer patients with COVID-19, as either survivor or non-survivor (14 studies) or severe events (1 study) ( Table 4 ). Of note, 3 out of 15 studies reported both clinical outcomes (survivor/non-survivor and severe events) ( Table 4) . Severe events were defined by 11 investigators as a composite endpoint defined based on the individual being admitted to the intensive care unit, or requiring invasive ventilation, or death [6, [14] [15] [16] .

The funnel plot (Supplementary Figure 1) and Egger's test (P =.17) showed no publication bias in the overall population. The quality of the cohort studies was assessed according to the NOS tool, which showed that 8 studies had high quality (scoring ranging between 7 to 9) (Supplementary Table 1 ), whereas 2 studies were of moderate quality (scoring ranging between 5 to 6). The five case series studies were considered as low quality.

The meta-analysis of 14 out of the 15 studies with reported death as outcome demonstrated the overall case fatality rate among COVID-19 patients with cancer was 22.4% (95% CI = 17.3% to 28.0%) (Figure 2) . We next sought to compare the case fatality rate of COVID-19 patients with cancer to that of COVID-19 patients without cancer, using three studies where death was recorded in both of these populations [14, 28, 29] .

Our analysis revealed that the case fatality rate of COVID-19 patients with cancer was 23.4% (95% CI = 9.7% to 40.5%) ( Supplementary Figure 2A) , whereas that of COVID-19 patients without cancer was 5.9% (95% CI = 1.9% to 11.7%) (Supplementary Figure   2B) . COVID-19 patients with cancer have a higher case fatality rate than COVID-19 patients without cancer ( Supplementary Figure 2A and 2B) , as well as that of general patient population with COVID-19 from recent published work [1, 32, 33] .

Of note, the case fatality rate in COVID-19 patients with cancer in Asia (China) is 20.0% (95% CI = 14.5% to 26.2%) (Supplementary Figure 2C) , which is similar to that of the rest of the world (Europe, the UK and USA) at 24.1% (95% CI = 16.1% to 33.2%) (Supplementary Figure 2D) . There was no difference observed in case fatality rate between Asia and the rest of the world. Statistically significant heterogeneity was demonstrated among the case fatality rates (Q = 113.5, P <.001, I 2 = 88.5%). The case fatality rate of 61.5% (95% CI = 31.6% to 86.1%) in He et al was the highest among all the individual studies. Potential contributing factors identified through this cohort include hematological malignancy, severe COVID-19 disease classification, and co-infections [28] .

The sensitivity analysis conducted by excluding 5 case series studies showed that the case fatality rate of COVID-19 patients with cancer was 21.6% (95% CI = 15.7% to 28.2%). As 2 of the cohort studies had moderate quality based on the NOS scores (scoring ranging between 5 to 6) (Supplementary Table 1) , we performed a further sensitivity analysis excluding these 2 studies. This showed that the case fatality rate of COVID-19 patients with cancer was 22.5% (95% CI = 16.2% to 29.4%). Neither of these above sensitivity analyses demonstrated an obvious change in case fatality rate of COVID-19 patients with cancer. In addition, the sensitivity analysis performed by using 'leave-one-out' approach did not change our result (Supplementary Figure 3) . 13 We performed a number of subgroup analyses on case fatality or severe event rate according to cancer type (lung, other solid or hematological cancer) and treatment type (chemotherapy, immunotherapy and radiotherapy). The overall case fatality rate in the lung cancer patients with COVID-19 was 32.9% (95% CI = 27.9% to 38.0%) (Figure 3A) , and the severe event rate was 57.2% (95% CI = 31.4% to 81.3%) (Supplementary Figure 2E) . In other types of solid cancer excluding lung, the overall case fatality and severe event rates were 17.2% (95% CI = 12.3% to 22.7%) ( Figure 3B ) and 59.7% (95% CI = 53.5% to 65.9%) (Supplementary Figure 2F) , respectively. In addition, the overall case fatality rate in hematological cancer patients was 34.2% (95% CI = 23.1% to 46.2%) ( Figure 3C) . No statistically significant heterogeneity was demonstrated among the case fatality rates in lung cancer patients with COVID-19 (Q = 6.3, P = .51, I 2 = 0.0%), whereas heterogeneity was observed in other types of solid cancer (Q = 21.6, P = .001, I 2 = 72.3%) or hematological cancer patients (Q = 34.6, P < .001, I 2 = 79.7%). It is worth noting that the case fatality rate in lung cancer is comparable to that of hematological cancer patients with COVID-19, whereas it is lower in other types of solid cancer. Furthermore, we examined the case fatality rate in the patients from individual studies, who underwent chemotherapy, surgery, immunotherapy, radiotherapy and targeted therapy actively or within the past three months when diagnosed with COVID-19. In patients treated with chemotherapy, surgery or immunotherapy, the case fatality rate was 25.6% (95% CI = 16.0% to 36.2%) (Figure 3D ), 27.6% (95% CI = 6.4% to 54.4%) (Figure 3E) , and 24.3% (95% CI = 15.3% to 34.2%) (Figure 3F) . The case fatality rate for patients under treatment of radiotherapy or targeted therapy was 20.5% (95% CI = 13.5% to 28.2%) ( Figure 3G) and 21.3% (95% CI = 9.0% to 35.8%) (Figure 3H) , respectively. In comparison, the case 14 fatality rate was similar among patients who were given different types of treatment.

Statistically significant heterogeneity was observed among the case fatality rates in patients treated with chemotherapy (Q = 31.8, P < .001, I 2 = 78.0%) and surgery (Q = 37.8, P < .001, I 2 = 86.8%), whereas no substantial heterogeneity was demonstrated in patients receiving treatment with immunotherapy (Q = 2.52, P = .77, I 2 = 0.0%), radiotherapy (Q = 2.62, P = .62, I 2 = 0.0%) or targeted therapy (Q = 2.52, P = .24, I 2 = 27.5%).

Next, we extracted the individual patient data of 150 subjects from available studies [6, 14, 15] and analyzed the associations between demographic or clinical characteristics and outcomes (survivor or non-survivor, or severe events). Univariate logistic regression was used to estimate the ORs of each variable including age, gender, comorbidities (hypertension, diabetes, or cardiovascular disease), or cancer type (hematological malignancy, lung or other solid cancer), or treatment (chemotherapy, immunotherapy, targeted therapy, radiotherapy or surgery) with outcomes ( Table 5) . Factors, including age, gender, hypertension and diabetes, which showed a statistically significant association with outcomes from univariate analysis, were included in the multivariate analysis ( Table 5) . 13.20) were associated with increased risk of severe events (a composite endpoint defined based on the individual being admitted to the intensive care unit, or requiring invasive ventilation, or death).

No association was found between cardiovascular disease and increased risk of severe events from COVID-19 compared with those with no comorbidity (Table 5) .

Similarly, there was no statistically significant difference in the increased risk of severe events comparing patients with lung cancer versus other solid cancer or hematological cancer, respectively ( Table 5 ). In addition, cancer patients on chemotherapy or surgery, or other anticancer treatment, were not associated with increased risk of severe events from COVID-19 compared with those not on active treatment (including patients with active tumor or previous malignancy) ( Table 5) . Furthermore, in the subgroup of patients with active tumor only, our analysis demonstrated that treatment (including chemotherapy, immunotherapy, targeted therapy, radiotherapy or surgery) was not associated with a higher risk of a poorer prognosis (Supplementary Table 2 ). In multivariate analysis, only being older than 65 years (OR = 3.16; 95% CI = 1.45 to 6.88) and male (OR = 2.29; 95% CI = 1.07 to 4.87) were associated with increased risk of severe events ( Table 5 ).

In summary, the occurrence of severe events including death in cancer patients with COVID-19 appears to be primarily accentuated by age, gender and co-existing comorbidities.

The rapid spread of COVID-19 has a substantial impact on cancer patients. Our To our knowledge, this is the first meta-analysis that systematically examined the largest aggregate of patients with cancer and COVID-19 to date, involving 3019 patients with a broad geographical distribution. These 15 individual cohorts are comprised of a diverse population in terms of age and gender distribution, cancer type, presence of comorbidities and status of active anticancer treatment. The findings in this study suggest that overall case fatality rate was estimated at 22.4% in the COVID-19 patients with cancer, which is higher than that of the COVID-19 patients without cancer at 5.9% in this study, as well as that of general patient population with COVID-19 from recent published work [1, 32, 33] . Age and gender appear to be significant risk factors associated with poorer prognosis.

One of the strengths of our meta-analysis is that we performed an extensive systematic review of 15 individual studies covering many geographical regions to reflect the global impact on cancer patients. The patients included in this meta-analysis are wellrepresented in ethnicity and geographical regions of residence, with nearly half from the 17 UK and Europe (41.0%), followed by the USA and Canada (35.7%) , and Asia (China, 23.3%). It is interesting to note that there is no difference in case fatality rate in cancer patients with COVID-19 between China and the rest of the world, highlighting a need for continuous data sharing and international collaboration on a global scale.

While recognizing the daunting fact that cancer patients have a higher death rate, an important question is which cancer types might be most vulnerable among all cases presented in these studies? Subgroup analysis on clinical outcomes in different cancer types indicated that case fatality rate is higher in lung or hematological cancer in comparison to other solid cancer. Similarly, some studies have also observed individuals with hematological or lung cancer had poorer prognoses than did those with solid tumors [14, 30] . Another interesting observation is although the severe events rate is similar in lung cancer patients compared with that of patients with other solid cancer, the case fatality rate of lung cancer is higher than that of other solid cancer. This suggests that lung cancer patients with COVID-19 may experience increased difficulty recovering from this disease once it progressed to a severe stage.

However, in our subsequent univariate analysis using available individual patient data, no statistically significant associations were found between cancer type and severe events rate, consistent with a recent report [16] . Considering the heterogeneity between different tumor subtypes identified as solid tumor in the cohorts analyzed, cautious interpretation of these results is necessary. Future analysis with a larger cohort of individual patient data is worthwhile and might offer new insight in guiding clinical management in high-risk cancer type populations.

One of the most important issues to address is whether patients should be advised to delay any anticancer treatment. It is inconclusive whether patients who received active chemotherapy, targeted therapy, or immunotherapy, or underwent surgery (defined as given within 4 weeks of COVID-19 diagnosis in many studies), had a higher risk of death or severe events. Several studies [6, 14, 30] from China indicated a positive association between treatment and increased deaths or severe events. All these studies are either relatively small cohorts or from a few hospitals restricted to a specific geographical region.

Based on our statistical analysis, we are not able to identify evidence supporting that cancer patients on cytotoxic chemotherapy are at an increased risk of severe events from COVID-19 disease compared with those not on active treatment. Despite the smaller sample size of these patients, similar findings were observed for surgery, immunotherapy, radiotherapy and targeted therapy. This is consistent with recent reports from several Another key question is what are the potential risk factors associated with COVID-19 related severe events in cancer patients? Of note, recent studies revealed that greater age, being male, or with comorbidities is associated with higher risk of death or severe 19 events in the population of general COVID-19 patients [34] [35] [36] . In line with the findings from these studies, our univariate analysis revealed being older than 65 years, male, the presence of any comorbidity, or hypertension, or diabetes were associated with an increased risk of severe events. However, in multivariate analysis, only being older than 65 years and male were at a higher risk of worse outcomes, supporting that age and gender are important predictors associated with poorer prognosis. Based on these findings, we suggest that this high-risk cancer population should be evaluated and treated in a clinical setting equipped with comprehensive medical resources.

There are a number of limitations herein. First, many clinical characteristics were not available (such as tumor staging) from individual studies, thus we were not able to examine the associations between some crucial factors and risk of death. Additionally, given the lack of information on some key characteristics which might affect the baseline prognosis of the patients, careful interpretation of results is needed. Second, there were heterogeneities in classifying the same variable in included studies, reducing the overall statistical power of the meta-analysis. For instance, one study combined chemotherapy and radiotherapy as one type of antitumor treatment [29] , whereas most listed chemotherapy as a separate type; all studies reported fatality rate but one described severe event rate [6] . Finally, we were not able to access the original data from all of the individuals in the 15 cohorts analyzed. It was therefore not possible to answer some key questions with high confidence, including whether cancer origins or treatment types are important predictors associated with death.

In aggregate, our analysis confirmed that patients with cancer are at increased risk of fatality and severe illness due to COVID-19. The occurrence of severe events and 20 death in cancer patients with COVID-19 appears to be primarily accentuated by age, gender and co-existing comorbidities. Best practice based on evidence will mitigate the impact of the COVID-19 pandemic on cancer patients and reduce the risk of morbidity or death from COVID-19.

None.

Role of the funder: Not applicable.

Disclosures: JS reports his conflicts at https://www.nature.com/onc/editors, none of which are relevant here. No other authors report a conflict of interest.

The data underlying this article are available in the article and in its online supplementary material. Yu, et al., 2020 (7) 12 66 (48-78) 2/10 Asia Barlesi, et al., 2020 (23) 137 61 79/58 Europe Garassino, et al., 2020 (10) 200 68 (62-75) a 59/141 Europe, USA, Asia Dai, et al., 2020 (14) 105 64 (55-69) a 48/57 Asia Martin-Moro, et al., 2020 (24) 34 73 (59-83) a 15/19 Europe Liang, et al., 2020 (6) 18 62 (56-68) a 6/12 Asia Mehta, et al., 2020 (26) 218 69 (10-92) 91/127 USA Yang, et al., 2020 (25) 52 63 (34-98) 24/28 Asia Ma, et al., 2020 (27) 37 62 (59-70) a 17/20 Asia Zhang, et al., 2020 (15) 28 65 (56-70) a 11/17 Asia He, et al., 2020 (28) 13 35 (23-53) a 6/7 Asia Tian, et al., 2020 (29) 232 64 (58-69) a 113/119 Asia Yang, et al., 2020 (30) 205 63 (56-70) a 109/96 Asia Kuderer, et al., 2020 (16) 928 66 (57-76) a 412/516 USA, Canada, Europe Lee, et al., 2020 (31) 800 69 (59-76) a 349/449 U.K. a Denotes IQR used to determine median age, otherwise shown as range. IQR, interquartile range. Barlesi, et al., 2020 (23) 47 ( Yang, et al., 2020 (25) 17 ( Barlesi, et al., 2020 (23) 12 ( (14) 22 ( He, et al., 2020 (28) 0 (0.0) 0 (0.0) 13 (100.0) 0 (0.0) 0 (0.0) 6 (46.2) 1 (7.7) 0 (0.0) Tian, et al., 2020 (29) 23 ( (8), mesothelioma (8) and carcinoid (4) . NR, not reported. 

Clinical Characteristics of Coronavirus Disease 2019 in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

An interactive web-based dashboard to track COVID-19 in real time

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Thoracic Cancers International COVID-19 Collaboration

The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer

NCI's Work to Advance Cancer Research while Responding to the COVID-19 Pandemic

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Meta-analysis in clinical trials

A basic introduction to fixed-effect and random-effects models for meta-analysis

Measuring inconsistency in metaanalyses

Bias in meta-analysis detected by a simple, graphical test

Outcome of cancer patients infected with COVID-19, including toxicity of cancer research

Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies

Clinical characteristics and outcomes of cancer patients with COVID-19

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study

COVID-19 in persons with haematological cancers

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Case-Fatality Rate and Characteristics of

Patients Dying in Relation to COVID-19 in Italy

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Factors associated with COVID-19-related death using OpenSAFELY

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy

Hematological Cancer Study (n = 605)